You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Musculoskeletal conditions
  5. Arthritis

Ustekinumab for treating active psoriatic arthritis

  • Technology appraisal guidance
  • Reference number: TA340
  • Published:  04 June 2015
  • Last updated:  03 March 2017
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination document

Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination document Psoriatic arthritis (active) - ustekinumab (Rapid Rev TA313) [ID819]: final appraisal determination document
12 March 2015
(280.18 Kb 21 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 09 March 2015

Back to top